VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that, an article titled “Non-hallucinogenic LSD derivative reduces depression symptoms in…


Previous articlePT401 – The Self-Entropic Broadening Theory: Understanding The Psychedelic State and Psychosis
Next articleApex Labs Meets Endpoints in First-of-its-Kind Take Home Microdose Psilocybin Clinical Trial